Navigation Links
Tiny soft medicine factories
Date:2/7/2014

A factory built of gel does not sound very durable. But the new type of micro-factories invented by researchers at Aarhus University do not have to last.

They will actually be placed inside a patient's body exactly where the medicine is required and they will gradually dissolve and disappear in the patient's urine once their mission is accomplished.

The prospects are so enormous that Associate Professor of Chemistry Alexander Zelikin, Aarhus University, has just been granted EUR 2 million to boost research and development in this field. The European Research Council (ERC) has awarded him an ERC Consolidator Grant.

Very advanced gel

The tiny factories consist of hydrogel, which is fundamentally a mixture of water and polymers with characteristics similar to gelatine. In this case we deal with some advanced variants of hydrogels: They must simultaneously be able to function as material for the small factories and contain the enzymes needed to produce medicine while the raw material is arriving at the factories.

There is basically nothing new in allowing enzymes to be in charge of the medical production - plenty of drugs are made of inactive substances which are not converted into active drugs until the liver or enzymes elsewhere in the body begins to break them down. They are called prodrugs.

An ordinary prodrug is, for example acetylsalicylic acid, which is the main ingredient in the common types of pain-relieving drug. They will not work until your liver has converted them into alicylic acid.

"The problem with this type of prodrugs is, however, that after the conversion they are typically sent into the blood in the intire body, so that only a fraction reaches the place which hurts. This problem can be solved in the process by creating prodrugs, which can only be transformed by specific enzymes - and then placing these enzymes in th eparticular part of the body which needs the drugs," explains Alexander Zelikin.

He will spend the EUR 2 million on developing two types of biodegradable factories:

Stents and particles

One of them is a new kind of stent which, among other things, is a term for the small metal meshes, which is operated into patients suffering from blockage of their coronary artery to keep it open after an angioplasty.

Alexander Zelikin's stents will be made of hydrogel instead of metal, because their primary purpose is not to keep a vein open, but to deliver medicine: the doctor injects a prodrug into the patient's vein, after which the enzymes in the stent convert it to, for example, a medicine against arteriosclerosis.

"The same enzymes will also be able to transform other sorts of prodrugs, so if one medicine doesn't work, you can switch to another without having to call the patient in for a new treatment," says Alexander Zelikin and continues:

"Metal stents coated with medicine are already in use - they just do not have the flexibility, that treatment which the enzymatic medicine factories have."

The second sort will consist of small particles, which initially can be used for the treatment of diseases such as cancer. The particles must be able to submit both medicine and for example contrast agents, so that they can be used simultaneously for treatment and diagnosis.

More specifically, the ERC grant will result in the employment of four PhD students and a postdoc.

The technology is pending patent and is being commercialised through Technology Transfer Office at Aarhus University.


'/>"/>
Contact: Alexander Zelikin
zelikin@chem.au.dk
45-23-29-79-86
Aarhus University
Source:Eurekalert

Related biology news :

1. Price Family Foundation funds research collaboration between Albert Einstein College of Medicine and University of Oklahoma
2. In vitro innovation: Testing nanomedicine with blood cells on a microchip
3. Vitamin A used in acne medicines may help autoimmune and transplant patients
4. 2014 Louis-Jeantet Prize for Medicine
5. UD-developed smart gels deliver medicine on demand
6. NPL links up with GlaxoSmithKline to support research into new medicines
7. Traditional Chinese Medicine in Singapore is Now Available at Urbanrehab Pte Ltd
8. Plant used in Chinese medicine fights chronic pain
9. New hope for stem cells, regenerative medicine emerges from the lab
10. Timing is everything in new nanotechnology for medicine, security and research
11. CNIO study chosen as discovery of the year in regenerative medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2016)... , November 22, 2016 According to the ... IRIS, Palm Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), ... published by MarketsandMarkets, the market is expected to grow from USD 10.74 ... CAGR of 16.79% between 2016 and 2022. ... ...
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/15/2016)... , Nov 15, 2016 Research and Markets ... Forecast to 2021" report to their offering. ... ... 16.18 Billion by 2021 from USD 6.21 Billion in 2016, growing ... Growth of the bioinformatics market is driven by the growing ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... 2016 The U.S. Biotechnology industry ... billion of revenue and some $890 billion of total ... global biopharmaceuticals, and this figure is expected to exceed ... up these four equities for assessment: Northwest Biotherapeutics Inc. ... ACAD ), Acorda Therapeutics Inc. (NASDAQ: ...
(Date:12/4/2016)... -- In five studies being presented today during the 58th ... in San Diego , researchers are ... of life-saving treatments to patients with a variety of ... therapies directly to the sites in the body where ... advantage over traditional, systemic methods. The studies highlight the ...
(Date:12/2/2016)... , Dec. 2, 2016 More than $4.3 million ... Helix Medals dinner ( DHMD ). The gala was held at ... New York City and honored Alan Alda ... respectively, to health and medicine and the public understanding of ... in 2006, the event has raised $40 million for the ...
(Date:12/2/2016)... -- CytRx Corporation (NASDAQ: CYTR ), a ... announced the appointment of Earl Warren Brien , ... healthcare investor, to its Board of Directors. ... strategic experience at the highest level," said Steven ... of the world,s leading orthopedic surgeons, Dr. Brien has ...
Breaking Biology Technology: